bioRxivMicrobiologyPreprint
Survival of the unfittest: clinical emergence of hyper-multidrug-resistant Nakaseomyces glabratus with rare nonfunctional Erg3 and Erg11 and severely impaired fitness.
Hans CarolusiD, Vladislav V. BiriukoviD, Jolien VreysiD, Celia Lobo Romero, Juan Paulo Herrera Avila, Rudy Vergauwen, Dimitrios SofrasiD, Giel VanreppeleniD, Lore Vinken, Basil Britto XavieriD, Toni GabaldóniD, Katrien LagrouiD, Reinout NaesensiD, Patrick Van DijckiD
Abstract
BackgroundNakaseomyces glabratus (Candida gabrata) poses a significant clinical challenge due to common drug resistance. We report a case of a complicated urinary tract infection (UTI) progressing to prostatitis and urosepsis, with the emergence of a hyper-multidrug-resistant isolate with low stress tolerance, slow growth and a short life span. This study elucidates the genetic mechanisms and phenotypic characteristics underlying antifungal hyper-resistance with strong fitness trade-offs, and explores potential alternative therapies for resistant UTIs. MethodsWhole-genome sequencing was performed to identify resistance-associated mutations and gene knock-out strains were generated to assess the relative impact of putative loss-of-function (LoF) mutations on antifungal resistance, fitness and membrane sterol composition. Drug susceptibility testing of the antibiotic nitroxoline and related compounds was conducted to evaluate it as a therapeutic alternative and study the mechanism of action. FindingsLoss-of-function mutations in ERG3 and ERG11 were identified and linked to the accumulation of 4,14-dimethylzymosterol and lanosterol instead of ergosterol. Engineered ERG3{Delta}+ERG11{Delta} strains recapitulated the clinical isolates hyper-multidrug resistance and associated fitness deficits. While ERG3{Delta} strains showed no resistance but enhanced thermotolerance, ERG11{Delta} and ERG3{Delta}+ERG11{Delta} strains exhibited multidrug resistance with severe fitness trade-offs. Interestingly, ERG3{Delta}+ERG11{Delta} strains showed mild resistance to flucytosine, but an additional FUR1 mutation in the clinical isolate most probably underlies hyper-resistance to flucytosine. The UTI antibiotic nitroxoline demonstrated high antifungal activity against all strains, and the LoF of ERG3 and/or ERG11 induced collateral sensitivity to this drug. Testing of related compounds suggest a mode of action beyond iron chelation. InterpretationThis case demonstrates that hyper-resistant strains of N. glabratus can emerge despite significant fitness costs and persist under prolonged antifungal therapy in specific clinical settings. These findings underscore the importance of vigilant antifungal resistance monitoring and highlight nitroxoline as a promising alternative treatment for complicated fungal UTIs. These results challenge the notion that strains with fitness deficits are clinically irrelevant and emphasize the need for novel therapeutic strategies including repurposed agents.
- organism: human
- assay: whole-genome sequencing
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Ergosterol-depleted clinical isolates of Nakaseomyces glabratus can develop multi-drug resistance without apparent fitness and virulence defects
Alexander Maximilian Aldejohann, Nadja Thielemann, … Ronny Martin·bioRxiv·Aug 28, 2025
- Antifungal resistance mechanisms and nosocomial transmission of Nakaseomyces glabratus: genomic investigation and observational study in Melbourne, Australia
Andrew Gador‐Whyte, Torsten Seemann, … Jason C. Kwong·bioRxiv·Jun 25, 2026
- Multiple mechanisms impact fluconazole resistance of mutant Erg11 proteins in Candida glabrata
Bao Gia Vu, Scott Moye-Rowley·bioRxiv·Jun 23, 2021
- Combined genetic and environmental factors shape the landscape of anti-fungal tolerance in Nakaseomyces glabratus
Sreyashi Acharjee, Edel M. Hyland·bioRxiv·Jul 2, 2025
- Acquired Amphotericin B Resistance Attributed to a Mutated ERG3 in Candidozyma auris
Lauryn Massic, Laura A. Doorley, … Mark Pandori·Antimicrobial Agents and ChemotherapyPeer-reviewed·Sep 22, 2025
- Epistasis at the cell surface: what is the role of Erg3 loss-of-function in acquired echinocandin resistance?
Hans Carolus, Judith Díaz-García, … Patrick Van Dijck·mBioPeer-reviewed·Sep 9, 2025